Yes Migy119 - it will or might get way worst before they get better revenues.
This is the hard reality points:
- we are in a risk averse period,
- Biotechs are high risk segments to begin with,
- Revenue is key to any company, let alone OSX - they are below par at this stage, so they have a very low fair value
- They have low to no cash, further dilution is possible. Investors know this.
Until they show revenue growth, all their prospects are fluff talk. It might work out - but we have to wait for a few years and track them.
Yes Migy119 - it will or might get way worst before they get...
Add OSX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.9¢ |
Change
-0.001(1.43%) |
Mkt cap ! $7.559M | |||
| Open | High | Low | Value | Volume |
| 6.9¢ | 7.0¢ | 6.8¢ | $159.7K | 2.306M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8582 | 6.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.0¢ | 14200 | 1 |
View Market Depth
| Last trade - 16.10pm 24/05/2024 (20 minute delay) ? |
|
|||||
|
Last
6.9¢ |
Change
-0.001 ( 1.43 %) |
||||
| Open | High | Low | Volume | ||
| 6.9¢ | 7.0¢ | 6.9¢ | 206338 | ||
| Last updated 15.48pm 24/05/2024 ? | |||||
| OSX (ASX) Chart |